

## Conclusions

The combination of CTA and perfusion correctly identifies patients with flow limiting CAD defined as  $\geq 50$  stenosis by ICA causing a perfusion defect by SPECT/MPI. The exclusion of patients with previous myocardial infarction or known CAD increased the diagnostic power of combined CTA–CTP in the non-invasive detection of flow limiting CAD defined by ICA-SPECT/MPI.

## Supplementary material

Supplementary material is available at *European Heart Journal* online.

## Funding

The study sponsor, Toshiba Medical Systems Corporation, was not involved in any stage of the study design, data acquisition, data analysis, or manuscript preparation.

**Conflict of interest:** M.D., A.deR., K.K., J.B., R.C., C.C., M.F.D.C., R.G., J.H., M.J., K.K., S.K., J. M.M., S.N., S.Y.T., A.V., V.C.M., K.Y., J.A.C.L., C.N., N.P., F.R., and A.A.-Z. report institutions receive grant support from Toshiba Medical System. M.D., S.Y.T., N.P., and J.H. are on the speaker's bureau for Toshiba Medical Systems. M.D., M.J., K.K., S.K., and R.G. report grant support from GE Healthcare. K.K. grant support form Philips Electronics, Bayer, Gerber, and Eisai. M.D. and J.A.C.L. grant support from Bracco Diagnostics. S.K. grant support from Daiichi-Sankyo Pharmaceutical. M.J. grant support from AZE and Ziosoft. M.D. grant support from: European Regional Development Fund, German Heart Foundation, Guerbet, German Science Foundation, and German Federal Ministry of Education and Research. M.D. is on the speaker's bureau for Guerbet, and Bayer-Schering. M.L. is a member of Speakers bureaus for Medtronic Inc, and Eesculap Akademie. M.D. consults for Guerbet and Richard George for ICON Medical Imaging. R.G. reports paid board membership for GE Healthcare and Astellas Pharma.

## References

The list of references is available in the online version of this paper.

## CARDIOVASCULAR FLASHLIGHT

doi:10.1093/eurheartj/eht519

Online publish-ahead-of-print 16 December 2013

### Excluding a giant coronary aneurysm by implantation of a covered stent

Mathias Possner<sup>1</sup>, Philipp A. Kaufmann<sup>1,2</sup>, Roberto Corti<sup>3†</sup>, and Oliver Gaemperli<sup>1,3\*</sup>

<sup>1</sup>Department of Radiology, Cardiac Imaging, University Hospital Zurich, Zurich, Switzerland; <sup>2</sup>Zurich Center for Integrative Human Physiology (ZHIP), University of Zurich, Zurich, Switzerland; and <sup>3</sup>Andreas Gruntzig Cardiac Catheterization Laboratories, Cardiovascular Center, University Hospital Zurich, Zurich, Switzerland

\* Corresponding author. Tel: +41 44 255 10 52, Fax: +41 44 255 44 01, Email: oliver.gaemperli@usz.ch

† R.C.'s current employer is HerzKlinik Hirslanden, Klinik Hirslanden, Zurich, Switzerland.

This paper was guest edited by Brahmajee Nallamothu (University of Michigan; bnallamo@umich.edu).

A 61-year-old gentleman underwent coronary computed tomography (CT) angiography (CCTA) for atypical chest pain, which revealed partially ectatic, diffusely diseased coronary arteries and a giant, eccentric, and partially thrombosed aneurysm in the proximal segment of the right coronary artery (RCA) (size:  $7 \times 5.5 \times 6$  cm; Panels A and B, arrows). On invasive angiography, the true size of the aneurysm was underestimated due to extensive thrombosis (Panels B and E, asterisk marking perfused part). The perfused aneurysm was connected to the RCA through a thin neck (Panel B, arrowhead), resembling a pseudoaneurysm rather than a true aneurysm. Myocardial perfusion SPECT revealed a non-transmural inferior scar without reversible ischaemia (Panel D: Hybrid SPECT/CT, black arrows).

Exclusion of the RCA aneurysm was performed by placement of a  $4.8 \times 26$  mm covered stent (Graftmaster RX, Abbott Vascular, Abbott Park, IL, USA). Distal diameter mismatch was corrected by post-dilatation with an oversized balloon-catheter (Avion Plus 6.0/20 mm, Medtronic Invatec, Frauenfeld, Switzerland) (Panel F). Repeat CCTA 4 months later showed a fully excluded aneurysm without further extravasation of contrast (Panel C). Triple therapy with aspirin, clopidogrel, and phenprocoumon was started for 3 months, followed by clopidogrel and phenprocoumon for another 9 months.

Coronary artery aneurysms, particularly of such giant dimensions, are rare findings on coronary angiograms and may be associated with extensive atherosclerosis or a history of vascular inflammatory disease (e.g. Kawasaki syndrome). Spontaneous ruptures of coronary aneurysms are exceedingly rare. However, due to the paucity of data, there is no evidence for the best treatment of such a giant aneurysm. In this particular case, the decision to exclude the aneurysm with a covered stent was taken to avoid rupture and distal embolization.

